Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 4,240 shares of the medical equipment provider’s stock after selling 1,163 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Hologic were worth $345,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cetera Investment Advisers lifted its stake in shares of Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock worth $1,595,000 after buying an additional 13,380 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Hologic by 51.4% during the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after purchasing an additional 176,006 shares during the last quarter. Andra AP fonden raised its holdings in shares of Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after purchasing an additional 66,000 shares during the last quarter. Swedbank AB raised its holdings in shares of Hologic by 5.2% during the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after purchasing an additional 80,575 shares during the last quarter. Finally, National Bank of Canada FI raised its holdings in shares of Hologic by 352.0% during the first quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider’s stock worth $22,474,000 after purchasing an additional 232,928 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Hologic stock opened at $78.60 on Monday. The firm has a 50 day simple moving average of $80.71 and a 200-day simple moving average of $78.26. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a market cap of $18.26 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 EPS. On average, analysts expect that Hologic, Inc. will post 4.27 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on HOLX shares. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Stephens reiterated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.